Research · Source update
TRIUMPH-3 explores retatrutide in cardiovascular disease
Source context: Read the linked original research or registry entry for study status and limitations.
The TRIUMPH-3 Phase 3 report assessed investigational retatrutide in severe obesity with established cardiovascular disease. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations.
What prompted this update?
The TRIUMPH-3 Phase 3 report assessed investigational retatrutide in severe obesity with established cardiovascular disease. MyDosePro reviewed the originating organization's statement to identify the reported results and their limitations. The originating source is Lilly TRIUMPH-2 and TRIUMPH-3 results, dated 2026-07-23.
What did the source report?
Lilly reported average weight reductions up to 22.6% over 80 weeks in the studied group. Lilly reported 21.6% and 22.6% average weight reduction with the 9 mg and 12 mg doses compared with 3.2% for placebo over 80 weeks.
How should the results be interpreted?
Weight loss alone is not evidence that the drug prevents heart attacks or strokes; those outcomes require their own assessment. Participants had class II–III obesity and established cardiovascular disease, with or without type 2 diabetes; weight reduction is not a proven reduction in clinical cardiovascular events.
What remains uncertain?
These findings apply to the specific study, date, population, product and endpoint described in the primary source. The source may be a sponsor announcement before full peer-reviewed publication. Check the original document and current regulatory status before drawing conclusions about personal treatment. Where a study or subgroup result was first released by a manufacturer, it should not be treated as independent confirmation of every claim; compare the full protocol, population, endpoints and subsequent publications.
What does this mean for patients?
This broadens the research population, not the approved indications. Treatment decisions depend on approved labeling, individual medical circumstances, availability and actual insurance benefits. MyDosePro offers educational context, not individualized prescribing or coverage confirmation.
The bottom line
This broadens the research population, not the approved indications.
Written and published by MyDosePro as an educational explanation of publicly available evidence. The linked primary source is dated 2026-07-23. We identify trial registrations separately from published results and do not provide individual prescribing advice.
Primary sourceLilly TRIUMPH-2 and TRIUMPH-3 results ↗
Additional evidenceSource event or update: 2026-07-23. Our interpretation is educational and does not replace medical or insurance advice.